Bifeprunox in the Treatment of Schizophrenia

A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00193713

Enrollment

Unknown

Registered

2005-09-19

Start date

2005-05-31

Completion date

2006-11-30

Last updated

2015-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

double-blind study in the treatment of schizophrenia

Brief summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Interventions

DRUGbifeprunox

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* diagnosis of schizophrenia * understand nature of study * able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion criteria

* current primary diagnosis other than schizophrenia * suicide risk * diagnosis or history of substance abuse * uncontrolled hypertension

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026